linjc16/ctgov huggingface dataset:
Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization

Study Overview
=================
Brief Summary
-----------------
Metformin should be administered with caution and could be potentially dangerous in infertile patients with PCOS who show a poor ovarian response and are undergoing gonadotropin-based ovarian stimulation. However, data that address this point are totally lacking. On the basis of these considerations, the aim of the current clinical trial was to test the hypothesis that metformin reduces the ovarian response in infertile patients with PCOS who have a potentially poor ovarian response and who undergo gonadotropin stimulation for IVF cycles.

Detailed Description
-----------------
Primary infertile patients with PCOS older than 35 years and/or with a basal follicle-stimulating hormone (FSH) level higher than 10 IU/L who were scheduled for IVF cycles were enrolled in the study protocol.

Official Title
-----------------
Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response

Conditions
-----------------
Infertility, PCOS, Prognosis for Poor Response

Intervention / Treatment
-----------------
* Drug: Metformin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCOS Prognosis for poor response Infertility Exclusion Criteria: Male factor infertility Tubal infertility

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Metformin<br>Metformin pre-treatment and co-administration | Drug: Metformin<br>* 500 mg three times daily<br>|
| Placebo Comparator: Placebo<br>Placebo pre-treatment and co-administration | Drug: Placebo<br>* 1 pill three times daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of cancellation due to low ovarian response | Number of cancelled cycles/total cycles | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stimulation length |  | one month | 
| Gonadotropins dose |  | one month | 
| Ovulation rate |  | one month | 
| pregnancy rate |  | one month | 
| Live-birth rate |  | nine months | 
| Adverse effects |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gonadotropins, infertility, IVF, metformin, PCOS, poor prognosis, poor responder
Prevalence Of Hyperhomocysteinemia In Thai Chronic Kidney Disease (CKD) Patients

Study Overview
=================
Brief Summary
-----------------
It is well recognized that patients with chronic kidney disease (CKD) have an increased risk for cardiovascular disease (CVD) and hyperhomocysteinemia appears to be a predictor of future CVD events. Hyperhomocysteinemia has been reported to bo of high prevalence in patients with CKD. The investigators aim to study the prevalence of hyperhomocysteinemia in Thai CKD patients by using Thai Screening and Early Evaluation of Kidney Disease (SEEK) study database and their relationship to CVD.

Detailed Description
-----------------
Ninety eight subjects were sampling from Thai SEEK study database Traditional Traditional risk factors of CVD such as total cholesterol, triglyceride, age, sex, history of smoking and blood pressure levels were examined and recorded. Stored sera of these subjects were analyzed for the total homocysteine (tHcy) level. Analysis of variance was used to evaluate the different of mean tHcy among groups

Official Title
-----------------
Prevalence Of Hyperhomocysteinemia In Thai CKD Patients And Relationship To Cardiovascular Events: Subgroup Analysis From Thai SEEK Study

Conditions
-----------------
Cardiovascular Disease, Hyperhomocysteinemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CKD stages 3-4 from Thai SEEK Study Exclusion Criteria: CKD stage 5

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CKD stage 3-4<br>CKD stage 3-4 from Thai SEEK study | |
| hyperhomocysteine group<br>CKD stage 3-4 from Thai SEEK study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of Homocysteine | Level of homocysteinemia according to each CKD level | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association of cardiovascular event to the level of homocysteine | Hugh level of homocysteine will have association with cardiovascular events or not | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperhomocysteinemia, Chronic kidney disease
Calculating the Volume of the Paravertebral Space

Study Overview
=================
Brief Summary
-----------------
Volume of the paravertebral spaces of the tharic and lumbar regions will be measured.

Detailed Description
-----------------
Paravertebral block is an effective regional anesthesia method and a golden standart technique for various operations. In addition, paravertebral block is a volume dependent technique. However, there are few cadaveric studies that investigates the volume of the paravertebral space. This study aims to calculate the volume of the paravertebral spaces of the lumbar and thoracic regions in the patients who had 3D computerized scan in Kocaeli University Hospital.

Official Title
-----------------
Calculating the Volume of the Paravertebral Space With 3D Computerized Tomography

Conditions
-----------------
Vertebral Disc Degenerative Disease

Intervention / Treatment
-----------------
* Diagnostic Test: 3D spine CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had a CT scan of the spine in our hospital Exclusion Criteria: Patients with scoliosis or known vertebral abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PV group<br>Patients who had a spine CT | Diagnostic Test: 3D spine CT<br>* CT scan of the spine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lumbar paravertebral space | Volume of the paravertebral space of the lumbar region | Baseline | 
| Thoracic paravertebral space | Volume of the paravertebral space of the thoracic region | Baseline |
Knowledge of Young Adults About Genital Herpes

Study Overview
=================
Brief Summary
-----------------
Despite sex education in schools and prevention campaigns concerning sexually transmitted infections, genital herpes remains frequent infection. In 2016, according to the World Health Organization, more than 490 million people worldwide were living with a genital herpes infection.

Detailed Description
-----------------
the aim of the study is to describe knowledge of adults aged 25 to 35 about genital herpes (symptoms, transmission, prevention).

Official Title
-----------------
Knowledge of Young Adults About Genital Herpes

Conditions
-----------------
Genital Herpes

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women Aged 25 to 35 Having sex or not Agreeing to participate in the study Exclusion Criteria: - Not agreeing to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| young adults<br>men and women aged 25 to 35 | Other: data collection<br>* Knowledge about genital herpes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| transmission | Modes of transmission of genital herpes (public toilets, home textiles, sexual transmission) | Day 0 | 
| symptoms | Types of symptoms of genital herpes (no symptom, rash, fever) | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Knowledge, Young adults, genital herpes
The Effect of Tranexamic Acid on Postoperative Blood Loss and Coagulation in Patients With Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; Double Blind Randomized Control Study

Study Overview
=================
Brief Summary
-----------------
The Effect of Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; double blind randomized control study.

Conditions
-----------------
Coronary Artery Occlusive Disease

Intervention / Treatment
-----------------
* Drug: Tranexamic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fifty patients undergoing OPCAB with preoperative hematocrit levels lower than 35% Exclusion Criteria: Patient who has Open heart surgery history before Thrombosis history Myocardial infarction (MI) within 7days recently Liver or Kidney disease been scheduled emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tranexamic acid<br>Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft | Drug: Tranexamic Acid<br>* 1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tranexamic acid significantly reduce the amount and incidence of homologous transfusion in anemic patients undergoing off-pump coronary artery bypass (OPCAB) |  | Check the amount 3 times before sugery and 24 hours after surgery |
A Prospective Cohort of Pulmonary Ground Glass Nodules Patients With Family History.

Study Overview
=================
Brief Summary
-----------------
The aim of the present prospective cohort study (GGN-F) is to study the family aggregation of pulmonary ground glass nodules via the questionnaire survey and to investigate the underlying genetic mechanism via the biobank.

Detailed Description
-----------------
In recent years, with the development of low-dose chest CT screening, more and more ground glass nodules have been found. Meanwhile, presenting as Ground-glass nodule (GGN), the early-stage lung adenocarcinoma patients with lung cancer family history have been emerging increasing in recent years in East Asian. This prospective cohort study, with both a cross-sectional and a longitudinal part, will include patients with pulmonary ground glass nodule, which were proven malignant disease. All participants will be asked to complete questionnaire to build the clinical database of GGN patients with detailed family history. Furthermore, blood and surgical tumor samples will be collected as a specific biobank. And the blood samples of other family members of participants will be collected, with their consent and knowledge.

Official Title
-----------------
Clinical Database and Biobank of Pulmonary Ground Glass Nodules Patients With Family History, a Prospective Cohort Study.

Conditions
-----------------
Lung Neoplasms, Family Research

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with informed consent; patients with pulmonary ground glass nodule. pathological proved early stage lung cancer. Exclusion Criteria: 1.not included in the inclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants<br>All the patients with proved malignant ground glass nodule will be enrolled. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prevalence of family aggregation of pulmonary ground glass nodule. | To investigate the aggregation of pulmonary ground glass nodule among first-degree relatives of participants via the questionnaire. | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Susceptibility genetic events related to the family aggregation of ground glass nodules. | To investigate the underlying susceptibility genetic loci which concern with familial inheritance of ground glass nodule. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ground glass nodule, Family aggregation, Hereditary susceptibility
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Official Title
-----------------
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of informed consent Asthmatics who has been prescribed Symbicort according to physician's judgement Usage of Symbicort should follow local prescribing information Exclusion Criteria: Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site) No previous enrolment in the present study

Ages Eligible for Study
-----------------
Minimum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Chinese asthma patient prescribed Symbicort® Turbuhaler® | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
HIV Self-Testing AND Uptake and Retention of PrEP Among Older Adolescent MSM and TGW

Study Overview
=================
Brief Summary
-----------------
This will be a prospective study that will enroll up to 600 older adolescent MSM and TGW from community-based clinics in Bangkok, Chonburi, Chiang Mai, and Songkhla.

Detailed Description
-----------------
All eligible participants will be followed up at month 3, 6, 9, and 12; month 6 and 12 will be mandatory clinic visits, while month 3 and 9 will be either clinic or a virtual visits. For participants accepting PrEP, additional follow-up visit at month 1, 2, 4, and 5 will be appointed; all visits will be either clinic or virtual visits. Study Sites The study will take place at the following community-based clinics: SWING DIC, Bangkok, Thailand RSAT DIC, Bangkok, Thailand SWING DIC, Chonburi, Thailand Sister DIC, Chonburi, Thailand Caremat DIC, Chiang Mai, Thailand MPlus DIC, Chiang Mai, Thailand RSAT DIC, Songkhla, Thailand

Official Title
-----------------
Study to Determine the Effect of HIV Self-testing on the Uptake of and Retention in Pre-exposure Prophylaxis Service Among Older Adolescent Men Who Have Sex With Men and Transgender Women

Conditions
-----------------
Men or Transgender Women Who Have Sex With Men

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thai nationality Age 15-19 years old Men or transgender women who have sex with men HIV-negative at the time of screening Have at least one of the following risks for HIV acquisition in the past 6 months: Any unprotected receptive anal sex with a male partner More than 5 male partners, regardless of condom use and serostatus Has had a bacterial sexually transmitted infection (STI) Any injected drug use Calculated creatinine clearance (CrCl) ≥ 75 mL/min, as estimated by the Cockcroft- Gault equation Alanine aminotransferase (ALT) ≤ 2.5 x ULN Have signed the informed consent form Exclusion Criteria: HIV-positive Hepatitis B infection as indicated by positive hepatitis B surface antigen (HBsAg) test at time of screening Known allergy/sensitivity to tenofovir or emtricitabine

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>300 To determine the effect of HIVST on PrEP uptake among older adolescent MSM and TGW | |
| Group 2<br>300 To determine the effect of HIVST on retention of older adolescent MSM and TGW in HIV service | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants starting PrEP among those who use and do not use HIVST |  | 3 years | 
| Proportion of participants taking PrEP retaining in care among those who use and do not use HIVST |  | 3 years |
Placebo Controlled Study of Sublingual Salvinorin A

Study Overview
=================
Brief Summary
-----------------
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.

Official Title
-----------------
A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A

Conditions
-----------------
Pharmaceutical Preparations

Intervention / Treatment
-----------------
* Drug: Salvinorin A
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, aged 21-45 Experienced with hallucinogenic amounts of SA Good physical and mental health Able to give adequate informed consent Exclusion Criteria: Any medical or psychiatric condition which, in the investigators' opinion, would preclude safe or consistent participation Significant acute or chronic medical disease Female who is pregnant, lactating, or plans to become pregnant during the study period and within one month after study drug administration

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dose Escalating<br> | Drug: Salvinorin A<br> <br> Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. |  | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Salvia divinorum, Salvinorin A